Business
Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor
Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastroin...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n \n \n \n Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nBORDER-TOP:1pt; BORDER-RIGHT:1pt; VERTICAL-ALIGN: BOTTOM; BORDER-BOTTOM:1pt; PADDING-LEFT:0.50em; BORDER-LEFT:1pt; PADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n SAN DIEGO, CA and CALGARY, AB, Oct. 27, 2020\n \n \n \n \n \n Multi-center trial to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple GI cancer indications\n \n \n \n \n Treatment aimed at\n \n 4.8M\n \n global GI cancer cases annually\n \n 1\n \n and the approximately 80% of GI cancer patients who do not respond to immune checkpoint inhibitor therapy currently\n \n \n \n \n Study builds on prior early findings of greater than 90% clinical benefit in colorectal and greater than 80% increase in progression-free survival in pancreatic cancer patients\n \n \n \n \n SAN DIEGO, CA\n \n and\n \n CALGARY, AB\n \n ,\n \n Oct. 27, 2020\n \n /CNW/ -- Oncolytics Biotech\n \n ®\n \n Inc. (NASDAQ: ONCY) (TSX: ONC) today announced a new multi-indication gastrointestinal (GI) cancer study to be managed by AIO, a leading academic cooperative medical oncology group based in\n \n Germany\n \n .  The phase 1/2 trial, known as GOBLET, will investigate the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq\n \n ®\n \n ), in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers.\n \n \n \n \n \n \"We are very excited for the opportunity to treat patients with pelareorep, which has the potential to address significant unmet needs across multiple challenging indications with poor prognoses in the GI cancer space,\" said\n \n Dirk Arnold M.D\n \n ., Ph.D., Director of the Asklepios Tumorzentrum...